Scarica l'app Stockscreener
24.40
1.69%
-0.42
Dopo l'orario di chiusura:
24.56
0.16
+0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria
Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha
DNLI SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Denali Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Denali Therapeutics Q2 Earnings Call Highlights - MarketBeat
Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue - TradingKey
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss - marketscreener.com
Denali Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M - marketscreener.com
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingView
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary - TradingView
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise - TradingView
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH - Stock Titan
BRIEF-Denali Therapeutics Q2 Operating Expenses USD 134.145 Million - TradingView
Denali Therapeutics earnings on deck: First drug sales in focus By Investing.com - Investing.com Nigeria
Denali Therapeutics Inc. (DNLI) Stock Analysis: Investors Eye 48% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Dimensional Fund Advisors LP Boosts Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) to Release Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI is ADAR1 Capital Management LLC's 10th Largest Position - MarketBeat
Denali Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Denali Therapeutics sells priority review voucher for $195 million gross proceeds - Bitget
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - The Manila Times
Denali Therapeutics Inc (DNLI) Cash Flow - TradingKey
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier - Stock Titan
Masters Capital Management LLC Sells 400,000 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Denali Therapeutics Inc (DNLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DNLI|Denali Therapeutics Inc|Price:24.400|Chg%:-0.420 - TradingKey
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Institutional Confidence - TradingKey
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36 - moomoo.com
Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News - Sahm
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance
🤔🤔🤔🤔🤔🤔🤔🤔 - Moomoo
Principal Financial Group Inc. Sells 45,637 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):